In recent years, the incidence rate of heart failure has been increasing year by year in China, and the prognosis is poor. In particular, acute heart failure has become the main cause of hospitalization for elderly patients. About 15% to 20% of them are new heart failure, while most of the others are the acute aggravation of the original chronic heart failure. The prognosis of acute heart failure is poor, and the re hospitalization rate is about 50%. A disease with such a high recurrence rate can be said to cause great damage to people and families.

So what is the reason for the high recurrence rate? Today, Xiao Nuo comes to discuss with you.

First. Let's first look at the process of acute heart failure.

The so-called positive inotropic drugs are a kind of drugs that can increase the contractile force of heart, increase the intensity and frequency of myocardial contraction, and improve the cardiac output. They usually have both pharmacological effects on peripheral blood vessels, so as to improve the hemodynamics of patients with heart failure and relieve the symptoms of heart failure.

Generally speaking, positive inotropic drugs can selectively enhance myocardial contractility and increase heart rate, which are mainly used to treat congestive heart failure and other cardiovascular emergencies.

But as far as the traditional positive inotropic drugs are concerned, there are still many side effects and limitations.

It can be seen from the figure that although the traditional positive inotropic drugs can correct the hemodynamic deterioration and improve the organ perfusion of patients with heart failure, improve the cardiac parameters and hemodynamic parameters of patients with heart failure, they are more likely to cause the increase of Ca2 + inflow, thus affecting the myocardial relaxation, inducing ventricular arrhythmia, increasing the myocardial oxygen consumption, myocardial ischemia and metabolic changes.

After the invention of a new drug, it has been confirmed by a number of studies, as well as significant clinical effects, and is also regarded as an ideal positive inotropic drug. This drug is zuoximendan produced by Chengdu shengnuo biopharmaceutical Co., Ltd.

Compared with the same type of drugs, zuoximendan can be said to be a "newcomer". Most hospitals do not have this drug, and even many grassroots doctors do not understand it. Most of them can only obtain some knowledge of drug use from academic conferences.

Different from the traditional positive inotropic drugs,Levosimendan is a calcium sensitizer. Its positive inotropic effect is independent of β - adrenergic stimulation. It can still increase the systolic force in patients with hypoperfusion after β - receptor blocker application. Its effect of improving clinical symptoms and prognosis in patients with acute heart failure is not inferior to that of dobutamine, which can significantly reduce the BNP level. It is suitable for low cardiac output or low perfusion Use as early as possible.

A number of studies have confirmed that the symptoms of heart failure patients have been significantly improved after the application of Levosimendan, the output of each stroke has increased, the left ventricular ejection fraction has increased, and the mortality has decreased significantly.

In addition to the application in acute heart failure, it also includes intractable heart failure, heart failure after acute myocardial infarction and cardiogenic shock. Clinically, it is also used to treat and prevent myocardial stunning after cardiac surgery, and even for the treatment of perioperative and septic shock patients in pediatric cardiac surgery.

Chengdu Shengnuo Biotechnology Co., Ltd. has "Chengdu polypeptide drug engineering technology research center" in Chengdu, mainly engaged in polypeptide, polypeptide drug and beauty peptide research. Our zero defect has passed the FDA certification, and now it has become the first-class professional peptide drug and product development, technology transfer, technical service and peptide drug industry in the scale production and export of China's parks.

Shengnuo bio PRODUCT

Best sales manager contact

About Shengnuo

Chengdu Shengnuo Biotechnology Co., Ltd. has "Chengdu polypeptide drug engineering technology research center" in Chengdu, mainly engaged in polypeptide, polypeptide drug and beauty peptide research. Our zero defect has passed the FDA certification, and now it has become the first-class professional peptide drug and product development, technology transfer, technical service and peptide drug industry in the scale production and export of China's parks.